We have not identified any relevant research documenting changes in LCAT in patients with NAFLD and osteoporosis, but studies in mouse models have shown that dysfunctional and/or disordered HDL can affect bone mass in several different ways. The gene discussed is LCAT; the disease is metabolic dysfunction-associated steatotic liver disease.